From neutral to overdrive?

Never let it be said that diabetes isn’t one wacky world. For weeks now, we’ve been noting that Novo Nordisk is being Novo Nordisk taking their sweet time getting the oral version of semaglutide to the FDA. Never known for being swift or aggressive the company may be in the verge of an about face. Per a report on the FirecePharma website;

“The Danish drugmaker is considering using a priority review voucher for the candidate, a company spokesman confirmed by email. Doing so would expedite semaglutide’s trip down the regulatory pathway—and hasten a head-to-head . . .

This content is restricted to subscribers. Please subscribe.

Already have an account? Please login.